a protein involved in the repair of mismatches in DNA. Binds PMS2 or MLH1 and MLH3. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50- MRE11-NBS1 protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts with MBD4. Interacts with EXO1. Defects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2; Turcot syndrome, an autosomal dominant disorder characterized by malignant tumors of the brain; Muir-Torre syndrome (MTS), a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy; lobular carcinoma in situ; endometrial cancer; and non-polyposis colorectal cancer. Note: This description may include information from UniProtKB.
Molecular Function: protein binding; ATPase activity; guanine/thymine mispair binding; MutSalpha complex binding; single-stranded DNA binding; ATP binding
Biological Process: ATP catabolic process; response to drug; oogenesis; mismatch repair; response to toxin; somatic hypermutation of immunoglobulin genes; negative regulation of mitotic recombination; isotype switching; spindle midzone assembly involved in meiosis; double-strand break repair via nonhomologous end joining; pachytene; poly(A) tail shortening; meiotic metaphase I plate congression; DNA damage response, signal transduction resulting in induction of apoptosis; meiotic recombination; response to hypoxia; male meiosis chromosome segregation; resolution of meiotic joint molecules as recombinants; spermatogenesis
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.